肿瘤防治研究2024，Vol.51Issue(3)：178-184,7.DOI:10.3971/j.issn.1000-8578.2024.23.1036
IDH突变和1p/19q共缺失型少突胶质细胞瘤临床病理特征和预后分析
Clinicopathologic Characteristics and Prognosis of Oligodendroglioma with IDH Mutation and 1p/19q Codeletion
摘要
Abstract
Objective To analyze the clinicopathological characteristics and prognosis of oligodendroglioma with IDH mutation and 1p/19q codeletion.Methods We collected the data of 54 oligodendroglioma patients with IDH mutation and 1p/19q codeletion.The patients'clinicopathological data,including age,histological grade,and tumor site,were analyzed for the effects on progression-free and overall survival.Results Among the 54 patients,46 cases were with tumor sites in one lobe,and eight cases involved tumor sites in more than two lobes.A total of 12 and 42 cases had WHO grades 2 and 3 oligodendroglioma,respectively.Detection by fluorescence in situ hybridization showed 1p/19q co-deletion in all cases.Immunohistochemical tests revealed diffuse and strong positive results for Olig2.All glial fibrillary acidic proteins were positive.p53 was strongly positive in six cases.ATRX was expressed in all 48 cases.Ki-67 proliferation index ranged from 5％to 60％.Sanger sequencing showed that all 54 cases had IDH gene mutations(40 cases were IDH1 mutations,and 14 were IDH2 mutations),and 33 cases had telomerase reverse transcriptase promoter mutations.Relapse and metastasis occurred in 16 patients during treatment.Univariate analysis indicated that the postoperative recurrence and metastasis interval of more than two years can prolong the progression-free and overall survival of patients.All 54 patients had a mean progression-free survival of 33.5 months and the mean overall survival of 40.7 months.Conclusion For oligodendroglioma with IDH mutation and 1p/19q codeletion,precision chemoradiotherapy after surgery can reduce the risk of progression,and the postoperative recurrence and metastasis interval is associated with the prognosis.关键词
少突胶质细胞瘤/病理特征/组织学分级/基因检测/预后Key words
Oligodendroglioma/Pathological features/Histological grading/Genetic testing/Prognosis分类
医药卫生引用本文复制引用
吴小延,王苏杰,王芳,杜紫明,邓玲..IDH突变和1p/19q共缺失型少突胶质细胞瘤临床病理特征和预后分析[J].肿瘤防治研究,2024,51(3):178-184,7.基金项目
National Natural Science Foundation of China(No.81602468) （No.81602468）
The Guangdong Basic and Applied Basic Research Foundation(No.2020A1515010313,2017A030310192) （No.2020A1515010313,2017A030310192）
Fundamental Research Funds for the Central Universities(No.17ykpy84) （No.17ykpy84）
Scientific Research Start-up Fund of the Hundred Talents Plan of Sun Yat-sen University(No.PT19050301) 基金项目:国家自然科学基金(81602468) （No.PT19050301）
广东省基础与应用基础研究基金(2020A1515010313,2017A030310192) （2020A1515010313,2017A030310192）
中山大学青年教师培育项目(17ykpy84) （17ykpy84）
中山大学百人计划引进人才科研启动经费(PT19050301) （PT19050301）
